首页> 外文期刊>The international journal of biochemistry and cell biology >A potent anti-thrombosis peptide (vasotab TY) from horsefly salivary glands
【24h】

A potent anti-thrombosis peptide (vasotab TY) from horsefly salivary glands

机译:一种来自蝇fly唾液腺的有效抗血栓形成肽(vasotab TY)

获取原文
获取原文并翻译 | 示例
           

摘要

Vasotab TY is a KGD (Lys-Gly-Asp)-containing peptide identified from salivary glands of the horsefly of Tabanus yao. We have previously reported that vasotab TY showed a strong vasodilator activity. In the present study, vasotab TY was found to inhibit platelet aggregation effectively. It completely inhibited platelet aggregation induced by adenosine diphosphate (ADP) at the concentration of 9.6 |xg/ml. Vasotab TY significantly reduced thrombus weight in rat arteriovenous shunt model and inhibited thrombosis in carrageenan-induced mouse tail thrombosis model in vivo. Vasotab TY competitively bound to glycopro-tein IIb/IIIa (GPIIb/IIIa) with eptifibatide, a well-known KGD-containing cyclic heptapeptide containing high specificity and high affinity for GPIIb/IIIa, suggesting that it is an antagonist of the fibrinogen receptor GPIIb/IIIa on the surface of platelet. The KGD motif in vasotab TY may facilitate the binding of it to GPIIb/IIIa. Vasotab TY showed a half-life of more than 1 h in vivo. It showed little side effects including little bleeding, no hemolytic activity on human blood red cells and no cytotoxicity on human keratino-cyte and THP-1 cells. Combined its vasodilator and platelet inhibitory functions, vasotab TY might be an excellent candidate for the development of clinical anti-thrombosis medicines.
机译:Vasotab TY是一种含有KGD(Lys-Gly-Asp)的肽,从塔巴努斯(Tabanus yao)the的唾液腺中鉴定出来。先前我们曾报道过vasotab TY显示出强大的血管扩张活性。在本研究中,发现vasotab TY可有效抑制血小板聚集。它以9.6μg/ ml的浓度完全抑制了由二磷酸腺苷(ADP)诱导的血小板聚集。 Vasotab TY可显着降低大鼠动静脉分流模型中的血栓重量,并在体内由角叉菜胶诱导的小鼠尾巴血栓形成模型中抑制血栓形成。 Vasotab TY与eptifibatide竞争性结合糖蛋白IIb / IIIa(GPIIb / IIIa),这是一种众所周知的含KGD的环状七肽,对GPIIb / IIIa具有高特异性和高亲和力,表明它是纤维蛋白原受体GPIIb的拮抗剂。 / IIIa在血小板表面。 vasotab TY中的KGD基序可以促进其与GPIIb / IIIa的结合。 Vasotab TY在体内的半衰期超过1小时。它显示出很少的副作用,包括几乎没有出血,对人血红细胞没有溶血活性,对人角蛋白细胞和THP-1细胞没有细胞毒性。结合其血管舒张剂和血小板抑制功能,血管舒他汀TY可能是临床抗血栓形成药物开发的绝佳候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号